REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Taigen Biopharmaceuticals Holdings Limit (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Taigen Biopharmaceuticals Holdings Limit Profile Updated: February 22, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Chinese Download a sample report

TaiGen Biopharmaceuticals Holdings Limit (“TaiGen Taiwan” or “TaiGen”) is a research-based and product-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases, cancer and diabetes-related complications.

Headquarters
7F, 138 Shin Ming Rd., Neihu Dist
Taipei City; Taipei City;

Contact Details: Purchase the Taigen Biopharmaceuticals Holdings Limit report to view the information.

Website: http://www.taigenbiotech.com

Basic Information
Total Employees:
Purchase the Taigen Biopharmaceuticals Holdings Limit report to view the information.
Outstanding Shares:
Purchase the Taigen Biopharmaceuticals Holdings Limit report to view the information.
Financial Auditors:
Purchase the Taigen Biopharmaceuticals Holdings Limit report to view the information.
Incorporation Date:
September 15, 2005
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
14.37%
Purchase this report to view the information.
13.6%
Purchase this report to view the information.
6.12%
Purchase this report to view the information.
0.01%
Purchase this report to view the information.
Subsidiaries
Taigen Biotechnology Co., Ltd.
100%
Company Performance
Financial values in the chart are available after Taigen Biopharmaceuticals Holdings Limit report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
263.57%▲
Total operating revenue
263.74%▲
Operating profit (EBIT)
53.59%▲
EBITDA
28.4%▲
Net Profit (Loss) for the Period
60.82%▲
Total assets
-11.83%▼
Total equity
-15.25%▼
Operating Profit Margin (ROS)
529.96%▲
Net Profit Margin
353.7%▲
Return on Equity (ROE)
6.25%▲
Quick Ratio
0.04%▲
Cash Ratio
-2.25%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo